The Latest
-
5 questions going into this week's biopharma earnings
Biogen, The Medicines Company and Bristol-Myers Squibb are among the companies presenting, with several issues likely to take center stage.
-
SponsoredThe evolving data landscape will transform healthcare: here are four trends to watch
Having data on where and how people live provides the power to influence people’s health status, so as tech companies race to collect and link this information, they’re reshaping how we view and deliver healthcare.
-
Biohaven blames Apotex for FDA rejection of ALS drug
Biohaven said it is working with the FDA to solve the manufacturing-related problems that led to a Complete Response Letter for the experimental drug.
-
Ultragenyx close to learning whether gene therapy gamble will pay off
Two therapies acquired in a 2017 buyout of Dimension are poised to enter late-stage testing, if results due soon look good.
-
Amgen, Allergan launch first US biosimilars of Roche's Herceptin and Avastin
Market entry of the copycat drugs will test Roche's preparation for competition to what for years have been among its top-selling products.
-
ViiV veteran science chief to step down
John Pottage has held the top science and medical roles at the HIV-focused drugmaker for ten years. Two ViiV executives, Kimberly Smith and Harmony Garges, will succeed him.
-
Novartis gives first glimpse at Zolgensma launch
Despite some signs of insurer pushback, the Swiss pharma indicated steady progress in rolling out the pricey gene therapy commercially.
-
Gilead, Amgen, J&J most likely to buy Otezla, Wall Street predicts
Analysts argue the inflammation drug, which Bristol-Myers has to unload to meet FTC demands, could go for around $5 billion to $10 billion.
-
MyoKardia cuts all ties to Sanofi
Buying back U.S. royalty rights could look cheap for the biotech if mavacamten turns out to be a blockbuster.
-
3 Gilead execs, including R&D head, to leave as leadership shake-up continues
Chief Scientific Officer John McHutchison, who was named to the senior role last March, will depart the company in about two weeks.
-
Catalent to help make Novartis' Zolgensma at Maryland site
The gene therapy is currently produced at an AveXis facility in Illinois, but Novartis is expanding its capacity in anticipation of growing demand.
-
As Trump's drug pricing plan falters, Dem challengers pitch ideas for 2020
Former Vice President Joe Biden and Sen. Kamala Harris both unveiled this week their plans to confront the drug industry.
-
Advocacy group pledges six-figure ad buy to support Trump drug price plan
Patients for Affordable Drugs relaunched a campaign which supports the Trump administration's proposed International Pricing Index for certain drugs.
-
Merck urges caution on use of its newly approved antibacterial
The FDA approval of triple therapy Recarbrio comes with a reminder that overuse of antibiotics can cause resistance.
-
Inovio cuts staff, research to buy time
A reduction in spending should help the biotech extend its cash runway, but delays to several key programs raise questions.
-
Xarelto falls into the donut hole
A 19% decline from 2018 sales was a dark cloud in an otherwise mostly positive quarterly earnings for Johnson & Johnson.
-
Novartis secures speedy review for sickle cell drug
Priority review from the FDA sets up an early 2020 decision on approval of crizanlizumab in the genetic blood disorder.
-
FDA warns Indian drug manufacturer Strides about document shredding
In a July warning letter, the regulator criticized the generics manufacturer for shoddy investigation of impurities and deficient quality practices.
-
Kite building out manufacturing as next cell therapy inches to market
A new facility will span 67,000 square feet and be located in Oceanside, California, tucked into an existing Gilead site for biologics.
-
GSK poses challenge to rival AstraZeneca with positive PARP data
Results from the PRIMA study show GSK's Zejula improved progression free survival when used as a frontline maintenance treatment for ovarian cancer.
-
Gilead forges closer ties with Galapagos in $5.1B deal
Eschewing a buyout, Gilead head Daniel O'Day instead opted for a partnership approach in his first major development deal as the biotech's CEO.
UPDATED: July 15, 2019 at 12:28 a.m. -
Neon to advance cancer vaccine after early results suggest added benefit
The Cambridge biotech aims to prove that adding its personalized vaccine to drugs like Opdivo can improve responses across several solid tumors.
-
AbbVie bets on early immuno-oncology asset
Acquiring the private group Mavupharma brings AbbVie a small-molecule agent that acts on the so-called STING pathway.
-
Amgen and Novartis halt Alzheimer's studies as faith in amyloid hypothesis dims
The setback in high-risk pre-symptomatic patients raises questions over use of anti-beta amyloid agents, even in a preventive setting.
-
Lilly's Shaw to head Gilead's cancer push as new CEO of Kite
The appointment of Shaw, whose departure as head of Eli Lilly's Bio-Medicines unit was announced Thursday, is one of Gilead CEO Daniel O'Day's first major moves.
